Vascular Biogenics Ltd. (NASDAQ:VBLT) could be among the worst stocks to invest in right now as the company shares are trading 3.5% or 0.053 points down from last closing price of $1.5, reaching $1.4475 at last check. Any clue why there is so much of action in the VBLT stock? The share price has dropped in 4 of the last 5 days and is up 20.97% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 27,921 shares, and in total 112021 shares valued at $162150 were seen changing hands compared with 84100 shares valued at $126150 recorded at the previous session. You should take into consideration that a greater volume on lower prices causes the situation where nobody wants to continue with their long position and wants to exit from the VBLT stock.

Vascular Biogenics Ltd. (VBLT) shares have notched a 3-month gain of about 20.97%, but has still advanced 25% year to date. By comparison, the stock added 15.38% over the past 12 months, while it jumped 19.05% over the 1 month. The company’s market cap is around $54.54M, with its short interest ratio standing at 0.47%.

In the current trading session for VBLT, the stock witnessed two major price actions, it rose to a high of $1.5 and was down as much as $1.4333 at one point. The high recorded is very low when compared to their 52-week high which is $0.93. The 52-week high is now at -23.82 distance from current price. Their recent low of $1.9 represents a 55.65% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for VBLT is $3.4, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Vascular Biogenics Ltd. earned $-0.5 per share in the trailing 12 months and has a P/E ratio of -2.9. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 22.34 and lower compared to the sector’s average of 31.82. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. VBLT also has P/S multiple of 87.72. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 0.25x.

VBLT‘s last price was up 14.08% as compared to the average trading price of 50 days recorded at $1.27 while enlarging the period to 200 trading days, the average closing price was $1.3. At present, there are 36.36 million in the total number of common shares owned by the public and among those 26.22 million shares have been available to trade. The percentage of shares being held by the company management was 26.93% while institutions stake was 27.6%. The company has generated negative returns on equity over the last 12 months (-37.2%). It managed to keep its gross profit margin at 71.4% over the past 12 months.

When assessing the full upside of the VBLT stock, there is another set of technicals that should be looked into and considered. Its 0.66% gain from moving average of $1.44 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0.68 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Vascular Biogenics Ltd. — 5 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $2.75 on shares of Vascular Biogenics Ltd. (NASDAQ:VBLT), which corresponds to 89.66% upside potential than its current market price of $1.4475 and implies potential despite the recent drop in the price. However, their current target price has fallen from $2.75 a month ago and is up handily from the consensus target of $2.67 a quarter ago.

In the last five years, the EPS of the company has been roughly 7.9%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.

Let’s briefly check the hedge fund interest towards VBLT stock. Sabby Management LLC trimmed position in the company after it dumped -50% or 239,362 shares of its common stock. The hedge fund now owns 119,681 shares worth $173,238, SEC documents show. Ladenburg Thalmann Financial Services Inc. shored up assets in the stock as 22495.5 shares have been purchased, increasing its stake by 66.7% to 37,500 shares which are currently valued at $54,281. In addition, CVI Holdings LLC recently reported that it now owns 908,770 shares making a total of $1,315,445 based on the recent price. This refelects a change of -16.9% in their ownership.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.